Adiposity assessed close to diagnosis and prostate cancer prognosis in the EPIC study.

Autor:	Cariolou M; Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK., Christakoudi S; Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK., Gunter MJ; Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK., Key T; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK., Pérez-Cornago A; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK., Travis R; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK., Zamora-Ros R; Unit of Nutrition and Cancer, Cancer Epidemiology and Research Programme, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain., Petersen KET; Danish Cancer Institute, Diet, Cancer and Health, Copenhagen, Denmark., Tjønneland A; Danish Cancer Institute, Diet, Cancer and Health, Copenhagen, Denmark.; Department of Public Health, University of Copenhagen, Copenhagen , Denmark., Weiderpass E; International Agency for Research on Cancer, Lyon, France., Kaaks R; Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany., Seibold P; Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany., Inan-Eroglu E; Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany., Schulze MB; Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.; Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany., Masala G; Clinical Epidemiology Unit, Institute for Cancer Research, Prevention, and Clinical Network, Florence, Italy., Agnoli C; Epidemiology and Prevention Unit, IRCCS National Cancer Institute Foundation, Milan, Italy., Tumino R; Hyblean Association for Epidemiological Research, AIRE ONLUS Ragusa, Ragusa, Italy., Di Girolamo C; Centre for Biostatistics, Epidemiology, and Public Health, Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy., Aizpurua A; Ministry of Health of the Basque Government, Sub directorate for Public Health and Addictions of Gipuzkoa, San Sebastián, Spain.; Biodonostia Health Research Institute, Epidemiology of Chronic and Communicable Diseases Group, San Sebastián, Spain., Rodriguez-Barranco M; Escuela Andaluza de Salud Pública, Granada, Spain.; Instituto de Investigación Biosanitaria ibs. GRANADA, Granada, Spain.; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Madrid, Spain., Santiuste C; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Madrid, Spain.; Department of Epidemiology, Murcia Regional Health Council, Murcia-IMIB, Spain., Guevara M; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Madrid, Spain.; Instituto de Salud Pública y Laboral de Navarra, Pamplona, Spain.; Navarra Institute for Health Research, Pamplona, Spain., Aune D; Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK.; Department of Nutrition, Oslo New University College, Oslo, Norway.; Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway., Chan DSM; Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK., Muller DC; Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK., Tsilidis KK; Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK.; Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece.
Jazyk:	angličtina
Zdroj:	JNCI cancer spectrum [JNCI Cancer Spectr] 2024 Sep 02; Vol. 8 (5).
DOI:	10.1093/jncics/pkae070
Abstrakt:	Background: Adiposity has been characterized as a modifiable risk factor for prostate cancer. Its association with outcomes after prostate cancer diagnosis, however, must be better understood, and more evidence is needed to facilitate the development of lifestyle guidance for patients with prostate cancer. Methods: We investigated the associations between adiposity indices close to prostate cancer diagnosis (up to 2 years before or up to 5 years after diagnosis) and mortality in 1968 men of the European Prospective Investigation into Cancer and Nutrition cohort. Men were followed up for a median of 9.5 years. Cox proportional hazards models were adjusted for age and year of diagnosis, disease stage and grade, and smoking history and stratified by country. Results: Each 5-unit increment in prediagnosis or postdiagnosis body mass index combined was associated with a 30% higher rate of all-cause mortality and a 49% higher rate of prostate cancer-specific mortality. Similarly, each 5-unit increment in prediagnosis body mass index was associated with a 35% higher rate of all-cause mortality and a 51% higher rate of prostate cancer-specific mortality. The associations were less strong for postdiagnosis body mass index, with a lower number of men in analyses. Less clear positive associations were shown for waist circumference, hip circumference, and waist to hip ratio, but data were limited. Conclusions: Elevated levels of adiposity close to prostate cancer diagnosis could lead to higher risk of mortality; therefore, men are encouraged to maintain a healthy weight. Additional research is needed to confirm whether excessive adiposity after prostate cancer diagnosis could worsen prognosis. (© The Author(s) 2024. Published by Oxford University Press.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu